+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: Retrospective analysis of an initial experience



Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: Retrospective analysis of an initial experience



Mayo Clinic Proceedings 71(12): 1150-1154



Objective: To study the possible deleterious systemic effects of gadolinium in patients with impaired renal function. Design: We retrospectively analyzed the routine laboratory data and clinical course of patients who had undergone a gadolinium-enhanced magnetic resonance imaging (MRI) examination of the brain and spine and had evidence of impaired glomerular filtration. Material and Methods: Between October 1988 and October 1992, 15,830 patients underwent gadolinium-enhanced MRI at our institution, 151 of whom had a serum creatinine value of more than 2 mg/dL. The clinical records of these 151 patients were thoroughly examined for the period from 3 days before to 30 days after the gadolinium-enhanced MRI examination. All data were analyzed in an attempt to detect any adverse events that could be related to free gadolinium as a result of dissociation from the chelating agent due to prolonged elimination times (that is, increased serum creatinine concentrations). In addition, we calculated the 90-day mortality rate for both the study group and a matched control population of 80 patients who had undergone MRI of the brain and spine before gadolinium was available. Results: The overall incidence of adverse events in the study group was 3.6%. No event was severe or life threatening-nausea and rash occurred in two patients each, and seizure and headache occurred in one patient each. These findings were not significantly different from those in previous studies performed in populations with normal elimination times. Moreover, no significant difference was noted in the 90-day mortality rate (14.6% of the study group) in comparison with that in the control group (13.8%). Conclusion: On the basis of this initial retrospective analysis, we were unable to detect any clinical deleterious effects of administration of gadolinium for MRI examination in patients with impaired renal function. Further investigation with prospective studies is needed to confirm these initial retrospective findings.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009512797

Download citation: RISBibTeXText

PMID: 8945485


Related references

Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency. Journal of Vascular and Interventional Radiology 18(3): 331-333, 2007

Gadolinium-DTPA-exposure-induced systemic inflammatory response (GEISIR) in patients with chronic renal insufficiency. 2007

Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrology, Dialysis, Transplantation 22(11): 3179-3185, 2007

Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark. British Journal of Dermatology 165(4): 828-836, 2011

Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 250(3): 618-628, 2009

Renal artery stenting using gadolinium-based arteriography in patients with baseline renal insufficiency. Journal of the American College of Cardiology 41(6 Suppl. A): 38A, 2003

Gadolinium-based contrast agents as an alternative at vena cavography in patients with renal insufficiency--early experience. Radiology 212(1): 280-284, 1999

Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 180(1): 85-89, 1991

Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. Rheumatology 49(4): 821-823, 2010

Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure (vol 22, pg 3179, 2007). 2008

Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment. British Journal of Haematology 128(5): 631-635, 2005

A retrospective analysis of the patients with acute renal failure treated at the Artificial Kidney Center. A thirteen-year experience. Materia Medica Polona. Polish Journal of Medicine and Pharmacy 11(4): 378-383, 1979

Retrospective analysis of factors predicting end-stage renal failure or death in patients with microscopic polyangiitis with mainly renal involvement. Clinical and Experimental Nephrology 18(5): 795-802, 2014

A retrospective analysis of the patients with acute renal failure treated at the artificial kidney center katowice poland a 13 year experience. Materia Medica Polona 11(4): 378-383, 1979

Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure. Ndt Plus 1(3): 193-194, 2008